Cilengitide treatment for malignant glioma: Current status and future direction

Neurologia Medico-Chirurgica

Volumn 52, Issue 8, 2012, Pages 539-547

  Kurozumi, Kazuhiko ^a   Ichikawa, Tomotsugu ^a   Onishi, Manabu ^a   Fujii, Kentaro ^a   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Cilengitide; Integrin; Invasion; Malignant glioma

Indexed keywords

ALPHAVBETA5 INTEGRIN; CEDIRANIB; CETUXIMAB; CILENGITIDE; ONCOLYTIC VIRUS; PROCARBAZINE; SUNITINIB; TEMOZOLOMIDE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL ADHESION; CONFERENCE PAPER; DISEASE MODEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; INTEGRINS; NEOPLASM INVASIVENESS; SNAKE VENOMS;

EID: 84865522116     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.52.539     Document Type: Conference Paper

References (63)

1. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE: Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11: 6270-6279, 2005
2. Alghisi GC, Ponsonnet L, Ruegg C: The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4: e4449, 2009
3. Avraamides CJ, Garmy-Susini B, Varner JA: Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617, 2008
4. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, Black PM: Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49: 380-390, 2001
5. Bello L, Giussani C, Carrabba G, Pluderi M, Costa F, Bikfalvi A: Angiogenesis and invasion in gliomas. Cancer Treat Res 117: 263-284, 2004
6. Bouchard V, Demers MJ, Thibodeau S, Laquerre V, Fujita N, Tsuruo T, Beaulieu JF, Gauthier R, Vezina A, Villeneuve L, Vachon PH: Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. J Cell Physiol 212: 717-728, 2007
7. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571, 1994
8. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994
9. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M: Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 86: 788-795, 2002
10. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL: Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62: 4263-4272, 2002
11. Chi A, Norden AD, Wen PY: Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 7: 1537-1560, 2007
12. Fink K, Mikkelsen T, Nabors LB, Ravin P, Plotkin SR, Schiff D, Hicking C, Picard M, Reardon DA: Longterm effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: a randomized phase IIa study [meeting abstract]. J Clin Oncol 28: 15s, 2010 (suppl; abstr 2010)
13. Fujii K, Kurozumi K, Ichikawa T, Yoshida K, Onishi M, Michiue H, Chiocca EA, Kaur B, Date I: The integrin antagonist cilengitide enhances anti-tumor effect of vasculostatin-expressing oncolytic virus. Poster presented at: Congress of Neurological Surgeons 2011 Annual Meeting; Oct 1-6, 2011; Washington, DC, USA. Available from: http://2011.cns.org/posterbrowser.aspx. Accessed Jun 26, 2012
14. Fung C, Lock R, Gao S, Salas E, Debnath J: Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 19: 797-806, 2008
15. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M: Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106: 147-153, 2012
16. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378, 1999
17. Heckmann D, Kessler H: Design and chemical synthesis of integrin ligands. Methods Enzymol 426: 463-503, 2007
18. Hood JD, Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100, 2002
19. ClinicalTrials. gov: registry and results database of federally and privately supported clinical trials. Available from: http://clinicaltrials.gov/ct2/home. Accessed Jun 26, 2012
20. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687, 2002
21. Inoue S, Ichikawa T, Kurozumi K, Maruo T, Onishi M, Yoshida K, Fujii K, Kambara H, Chiocca EA, Date I: Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg Epub 2011 Nov 7
22. Jouanneau E: Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 62: 31-52, 2008
23. Kireeva ML, Lam SC, Lau LF: Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. J Biol Chem 273: 3090-3096, 1998
24. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A, Chiocca EA, Kaur B: Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16: 1382-1391, 2008
25. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, Kaur B: Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781, 2007
26. Leask A, Abraham DJ: All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119: 4803-4810, 2006
27. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA: Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 117: 1101-1107, 1992
28. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570, 2000
29. Lomonaco SL, Finniss S, Xiang C, Lee HK, Jiang W, Lemke N, Rempel SA, Mikkelsen T, Brodie C: Cilengitide induces autophagy-mediated cell death in glioma cells. Neuro Oncol 13: 857-865, 2011
30. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE: Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26: 919-924, 2008
31. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, LaugWE: Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48: 151-157, 2001
32. Mas-Moruno C, Rechenmacher F, Kessler H: Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10: 753-768, 2010
33. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M: Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 11: 747-756, 2009
34. Meyer A, Auernheimer J, Modlinger A, Kessler H: Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 12: 2723-2747, 2006
35. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL: Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124: 2719-2727, 2009
36. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J: In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 87: 716-723, 2000
37. Mitjans F, Sander D, Adan J, Sutter A, Martinez JM, Jaggle CS, Moyano JM, Kreysch HG, Piulats J, Goodman SL: An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 108(Pt 8): 2825-2838, 1995
38. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi M, Ruegg C: CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 68: 7323-7331, 2008
39. Nabors LB, Fink K, Reardon DA, Lesser GJ, Trusheim J, Raval SN, Hicking C, Picard M, Mikkelsen T: Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Protocol of a multicenter, randomized, open-label, controlled phase II study [meeting abstract]. J Clin Oncol 28: 15s, 2010 (suppl; abstr TPS151)
40. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25: 1651-1657, 2007
41. Oliveira-Ferrer L, Hauschild J, FiedlerW, Bokemeyer C, Nippgen J, Celik I, Schuch G: Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 27: 86, 2008
42. Onishi M, Ichikawa T, Kurozumi K, Date I: Angiogenesis and invasion in glioma. Brain Tumor Pathol 28: 13-24, 2011
43. Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date I: Anti-angiogenic and anti-invasive effect of cilengitide on experimental glioma. Poster presented at: Congress of Neurological Surgeons 2011 Annual Meeting; Oct 1-6, 2011; Washington, DC, USA. Available from: http://2011.cns.org/posterbrowser. aspx. Accessed Jun 26, 2012
44. Penas-Prado M, Gilbert MR: Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 7: 641-661, 2007
45. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M: Transforming growth factors beta(1) (TGF-beta(1) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 268: 607-611, 2000
46. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610-5617, 2008
47. Reardon DA, Nabors LB, Stupp R, Mikkelsen T: Cilengitide: an integrin-targeting arginine-glycineaspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17: 1225-1235, 2008
48. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R: Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 7: 339-354, 2011
49. Schaller MD: Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 1540: 1-21, 2001
50. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC, Goldbrunner RH: Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18: 378-386, 2008
51. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E: Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69: 3308-3316, 2009
52. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 2712-2718, 2010
53. Stupp R, Van Den BentMJ, Erridge SC, Reardon DA, Hong Y, Wheeler H, Hegi M, Perry JR, Picard M, Weller M: Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, openlabel, controlled phase III trial (CENTRIC) [meeting abstract]. J Clin Oncol 28: 15s, 2010 (suppl; abstr TPS152)
54. Tabatabai G, WellerM, Nabors B, PicardM, Reardon D, Mikkelsen T, Ruegg C, Stupp R: Targeting integrins in malignant glioma. Target Oncol 5: 175-181, 2010
55. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE: alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98: 690-697, 2002
56. Takada Y, Ye X, Simon S: The integrins. Genome Biol 8: 215, 2007
57. Tate MC, Aghi MK: Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6: 447-457, 2009
58. Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P, Graziani G: The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 19: 1039-1043, 2008
59. Varner JA, Cheresh DA: Integrins and cancer. Curr Opin Cell Biol 8: 724-730, 1996
60. Varner JA, Cheresh DA: Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 69-87, 1996
61. Wild-Bode C, Weller M, Wick W: Molecular determinants of glioma cell migration and invasion. J Neurosurg 94: 978-984, 2001
62. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563, 2004
63. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE: Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59: 1304-1312, 2006